Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms by Histologic Type 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1

Interventions

ponatinib 4fludarabine 4Cyclophosphamide 3fludarabine phosphate 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Imatinib Mesylate 2Busulfan 2Bone Marrow Transplantation 2trametinib 1tetulomab tetraxetan lu-177 1ruxolitinib 1pertuzumab 1nirogacestat 1nilotinib 1gilteritinib 1emvododstat 1dabrafenib 1bosutinib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × emvododstat × Other hematologic neoplasm × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡